Stockscreener 앱 받기
11.30
2.08%
0.23
시간 외 거래:
11.30
전일 마감가:
$11.07
열려 있는:
$10.57
하루 거래량:
97,910
Relative Volume:
0.62
시가총액:
$393.15M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+26.82%
1개월 성능:
-17.46%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$10.07
$11.98
1주일 범위
$8.60
$11.98
52주 변동 폭
$7.255
$24.90
Sionna Therapeutics Inc Stock (SION) Company Profile
명칭
Sionna Therapeutics Inc
전화
617-819-2020
주소
21 HICKORY DRIVE, SUITE 500, WALTHAM
SION을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
11.30 | 393.15M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-04 | 개시 | Guggenheim | Buy |
| 2025-03-04 | 개시 | Stifel | Buy |
| 2025-03-04 | 개시 | TD Cowen | Buy |
Sionna Therapeutics Inc 주식(SION)의 최신 뉴스
Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings - insights.citeline.com
In 2025, biotech IPOs were supposed to bounce back. It hasn't happened yet. - The Business Journals
Sionna Therapeutics (NASDAQ:SION) Trading Down 4.2%What's Next? - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Reaches New 1-Year Low on Disappointing Earnings - Defense World
Stifel maintains Buy rating on Sionna Therapeutics stock at $32 target - Investing.com Australia
SEC Form 10-K filed by Sionna Therapeutics Inc. - Quantisnow
Form 10-K Sionna Therapeutics, For: Dec 31 - StreetInsider
Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
SIONSionna Therapeutics Latest Stock News & Market Updates - StockTitan
Pre-market Movers: REVB, QSI, EYEN, NAOV ... - RTTNews
Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month - Insider Monkey
Top 10 Insider Purchases Last Month - Insider Monkey
Sionna Therapeutics, Inc.’s Quiet Period To Expire on March 19th (NASDAQ:SION) - Defense World
February financings slowing, but year outpaces 2022-2023 - BioWorld Online
Guggenheim Initiates Coverage on Sionna Therapeutics (NASDAQ:SION) - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
Investorideas.com adds New IPOs in Biotech, Technology, Homebuilder, Aerospace, Sports - Investorideas.com newswire
Is Sionna Therapeutics, Inc. (SION) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
Stifel Nicolaus Initiates Coverage on Sionna Therapeutics (NASDAQ:SION) - Defense World
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
Sionna Therapeutics (NASDAQ:SION) Now Covered by Stifel Nicolaus - MarketBeat
TD Cowen Initiates Sionna Therapeutics at Buy -March 04, 2025 at 07:57 am EST - Marketscreener.com
Guggenheim Initiates Sionna Therapeutics at Buy With $45 Price Target -March 04, 2025 at 07:58 am EST - Marketscreener.com
Stifel Initiates Sionna Therapeutics at Buy With $32 Price Target -March 04, 2025 at 07:57 am EST - Marketscreener.com
TD Cowen initiates Sionna Therapeutics stock with Buy rating By Investing.com - Investing.com UK
Goldman Sachs starts Sionna Therapeutics with Early-Stage Biotech designation - TipRanks
Sionna Therapeutics: Promising NBD1 Stabilizers Poised to Challenge Vertex in the $11 Billion CF Market - TipRanks
Sionna Therapeutics: Innovative NBD1 Stabilizers and Strategic Synergies Drive Buy Rating - TipRanks
Guggenheim sets Sionna stock Buy rating, $45 target By Investing.com - Investing.com Canada
Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
10 Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
Sionna Therapeutics’ NBD1 stabilizers hold potential for cystic fibrosis - The Pharma Letter
Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market - Yahoo Finance
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference - The Manila Times
Can This Clinical-Stage CF Treatment Developer Disrupt a $10B+ Market? Key Presentation Coming - Stock Titan
Sionna Therapeutics (SION) Surges in Nasdaq Debut Before Paring Gains - HPBL
Atlas Venture Fund Xi L.P Reports 6.5% Stake In Sionna Therapeutics As Of Feb 10 - Marketscreener.com
The Surprising Stock Insiders Can’t Stop Buying: What’s the Hype? - MotoPaddock
Sionna Therapeutics: The Biotech Stock Insiders Are Snapping Up! - Smartphone Magazine
Sionna Therapeutics: The Under-the-Radar Insider Favorite You’ve Been Missing - Anexartiti
Biopharma Gamble: Why Insiders Are Betting Big on Sionna Therapeutics - DSA
Why Insiders Are Betting Big on Sionna Therapeutics This Year - Bit Perfect Solutions
The Biopharma Gamble: Why Insiders Are Banking on Sionna Therapeutics - Elblog.pl
Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year? - Insider Monkey
10 Stocks Insiders Are Buying This Year - Insider Monkey
A Buffett Buy, a Biotech IPO, and Other Big Insider Buying - 24/7 Wall St.
Sionna therapeutics sees $20.25 million stock purchase by TPG - MSN
Sionna Therapeutics’ $219.2 Million Upsized IPO - Global Legal Chronicle
Sionna Therapeutics Inc (SION) 재무 분석
Sionna Therapeutics Inc (SION)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):